Previous Close | 21.87 |
Open | 22.09 |
Bid | 22.05 x 200 |
Ask | 22.14 x 500 |
Day's Range | 21.72 - 22.36 |
52 Week Range | 20.67 - 42.48 |
Volume | |
Avg. Volume | 1,270,900 |
Market Cap | 2.741B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.77 |
Earnings Date | May 09, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.38 |
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.
PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.